PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 02/21/2017 06:09:50)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 21, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 








Item 7.01 Other Events.
 
On February 21 and 22, 2017, PDL BioPharma, Inc. (the Company) will make presentations and participate in conferences with investors and analysts in connection with the 2017 RBC Capital Market's Global Healthcare Conference in New York, New York. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2015 Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2016, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Presentation






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ John P. McLaughlin
 
 
John P. McLaughlin
 
 
President and Chief Executive Officer




Dated: February 21, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 
Presentation





Exhibit 99.1

SLIDE1A31.JPG





SLIDE2A31.JPG





SLIDE3A31.JPG





SLIDE4A31.JPG





SLIDE5A31.JPG





SLIDE6A31.JPG





SLIDE7A31.JPG





SLIDE8A29.JPG





SLIDE9A27.JPG





SLIDH56.JPG





SLIDH57.JPG





SLIDH58.JPG





SLIDH59.JPG





SLIDH60.JPG





SLIDH61.JPG





SLIDH62.JPG





SLIDH63.JPG





SLIDH64.JPG





SLIDH65.JPG





SLIDH66.JPG





SLIDH67.JPG





SLIDH68.JPG





SLIDH69.JPG





SLIDH70.JPG





SLIDH71.JPG





SLIDH72.JPG





SLIDH73.JPG





SLIDH74.JPG





SLIDH75.JPG





SLIDH76.JPG





SLIDH77.JPG





SLIDH78.JPG





SLIDH79.JPG





SLIDH80.JPG





SLIDH81.JPG





SLIDH82.JPG





SLIDH83.JPG





SLIDH84.JPG





SLIDH85.JPG





SLIDH86.JPG





SLIDH87.JPG





SLIDH88.JPG





SLIDH89.JPG





SLIDH90.JPG